STAT 3 and 5 role in GC cytokine mediated latency III LMP1 promoter epigenetic remodeling.

Abstract

(A) Schematic diagram of LMP1 promoter STAT binding sites, S1, S2 and S3 [58]. (B-C) Chromatin immunoprecipitation (ChIP) qPCR analysis of STAT3 (B) or STAT5 (C) LMP1 promoter occupancy in GM12878 mock treated or treated with IL-15 or IL-21 for six days. (D-E) ChIP-qPCR analysis of LMP1 promoter H3K27Ac (D) or H2AK119Ub (E) epigenetic mark abundances in GM12878 expressing control versus STAT3/5A/5B targeting sgRNA, mock treated or treated with IL-15 or IL-21 for six days. (F-G) ChIP-qPCR analysis of LMP2 promoter H3K27Ac (F) or H2AK119Ub (G) abundances in GM12878 expressing control versus STAT3/5A/5B targeting sgRNA, mock treated or treated with IL-15 or IL-21 for six days. (H-I) ChIP-qPCR analysis of LMP1 promoter H3K27Ac (H) or H2AK119Ub (I) abundances in Mutu I expressing control sgRNA versus STAT3 targeting sgRNA, mock treated or treated with IL-21 for one day. All ChIP results are presented as % input mean ± SD from n = 3 replicates. *p p p < 0.001.</p